Edition:
Deutschland

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,347JPY
10 Jul 2020
Change (% chg)

¥-19 (-1.39%)
Prev Close
¥1,366
Open
¥1,380
Day's High
¥1,382
Day's Low
¥1,347
Volume
1,011,500
Avg. Vol
1,180,122
52-wk High
¥2,219
52-wk Low
¥1,166

About

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Company operates in four segments. The Japan segment manufactures and sells medical drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated... (more)

Buy/Sell

Sell Hold Buy
3.44 Mean rating from 9 analysts

Overall

Beta: 0.76
Market Cap(Mil.): ¥604,410.31
Shares Outstanding(Mil.): 397.90
Dividend: 11.00
Yield (%): 1.18

BRIEF-Myovant Sciences Announces FDA Acceptance Of New Drug Application For Prostate Cancer Treatment

* MYOVANT SCIENCES ANNOUNCES PRIORITY REVIEW AND FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ONCE-DAILY, ORAL RELUGOLIX FOR ADVANCED PROSTATE CANCER

BRIEF-U.S. FDA Approves Kynmobi For Treatment Of "Off" Episodes In Patients With Parkinson's Disease To Sunovion

* U.S. FDA APPROVES KYNMOBI FOR ACUTE, INTERMITTENT TREATMENT OF “OFF” EPISODES IN PATIENTS WITH PARKINSON’S DISEASE TO SUNOVION PHARMACEUTICALS Source text: (https://bit.ly/2LNrbwl) Further company coverage:

UPDATE 1-U.S. FDA approves Parkinson's treatment from Sunovion Pharma

May 21 The U.S. Food and Drug Administration on Thursday approved a sublingual film from Sunovion Pharmaceuticals Inc, a unit of Japan-based Sumitomo Dainippon Pharma, for the treatment of "off" episodes in patients with Parkinson's disease, the company said.

BRIEF-Aquestive Says Expect To Receive Between Up To $100 Million Of Non-Dilutive Capital From Monetization Of Royalty Stream

* AQUESTIVE THERAPEUTICS ADVANCES ROYALTY MONETIZATION PLAN AS SUNOVION PHARMACEUTICALS’ APOMORPHINE SUBLINGUAL FILM THERAPY RECEIVES FDA APPROVAL

U.S. FDA approves Parkinson's treatment from Sunovion Pharma

May 21 The U.S. Food and Drug Administration on Thursday approved a sublingual film from Sunovion Pharmaceuticals Inc, a unit of Japan-based Sumitomo Dainippon , for the treatment of "off" episodes in patients with Parkinson's disease, according to a label published by the agency.

BRIEF-Roivant Provides Updates For Pivotal Breathe Clinical Trial Evaluating Gimsilumab In COVID-19 Patients

* ROIVANT PROVIDES UPDATES FOR PIVOTAL BREATHE CLINICAL TRIAL EVALUATING GIMSILUMAB IN COVID-19 PATIENTS FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME

BRIEF-Sumitovant Biopharma Reports Key Clinical And Regulatory Milestones By Myovant Sciences

* SUMITOVANT BIOPHARMA - REPORTS KEY CLINICAL AND REGULATORY MILESTONES BY MYOVANT SCIENCES

BRIEF-Poxel End-March Cash And Cash Equivalents Down At 36.9 Million Euros

* POXEL ANNOUNCES FIRST QUARTER 2020 FINANCIAL AND CORPORATE UPDATE

BRIEF-Roivant Doses First Patient In Trial Evaluating Gimsilumab In Covid-19 Patients For Treatment Of ARDS

* ROIVANT DOSES FIRST PATIENT IN PIVOTAL BREATHE CLINICAL TRIAL EVALUATING GIMSILUMAB IN COVID-19 PATIENTS FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.07%
Rohstoffe -0.11%
Industrie -0.17%
Konjunktur abhängige Waren & Dienstleistungen -0.03%
Konjunktur unabhängige Waren & Dienstleistungen -0.09%
Finanzindustrie +0.00%
Pharma +0.02%
Technologie +0.06%
Telekommunikation +0.13%